Proveris Scientific establishes new European headquarters
Ivan Prince, recently appointed as manager, services and support for the regions, will drive forth this mission and play a role in devising and executing Proveris’s future plans
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. DSM’s XD technology has been developed as